215 related articles for article (PubMed ID: 26095486)
21. Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy.
Abe M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hirashima Y
Biomed Res Int; 2015; 2015():956785. PubMed ID: 26425564
[TBL] [Abstract][Full Text] [Related]
22. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
[TBL] [Abstract][Full Text] [Related]
24. Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?
Chiu L; Chow R; DeAngelis C; Lock M; Simone CB
Ann Palliat Med; 2021 Mar; 10(3):2540-2547. PubMed ID: 33440973
[TBL] [Abstract][Full Text] [Related]
25. The emerging role of olanzapine in paediatric CINV control: A review.
Barušić AK
Medicine (Baltimore); 2022 Dec; 101(50):e32116. PubMed ID: 36550859
[TBL] [Abstract][Full Text] [Related]
26. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting.
Oo TH; Hesketh PJ
Nat Clin Pract Oncol; 2005 Apr; 2(4):196-201. PubMed ID: 16264934
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and cost: avoiding undertreatment of chemotherapy-induced nausea and vomiting.
Viale PH; Grande C; Moore S
Clin J Oncol Nurs; 2012 Aug; 16(4):E133-41. PubMed ID: 22842698
[TBL] [Abstract][Full Text] [Related]
28. Effects of low-dose olanzapine on duloxetine-related nausea and vomiting for the treatment of major depressive disorder.
Zhong Z; Zhang Y; Han H; Huang Z; Wang J; Chen M; Zhang J
J Clin Psychopharmacol; 2014 Aug; 34(4):495-8. PubMed ID: 24943388
[TBL] [Abstract][Full Text] [Related]
29. Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer.
Alderman B; Hui D; Mukhopadhyay S; Bouleuc C; Case AA; Amano K; Crawford GB; de Feo G; Sbrana A; Tanco K; To J; Garsed J; Davis M
Support Care Cancer; 2022 Dec; 31(1):39. PubMed ID: 36525085
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Olanzapine for Symptom Relief in Cancer Patients.
Nakagawa N; Suzuki M
J Pain Palliat Care Pharmacother; 2022 Dec; 36(4):216-222. PubMed ID: 36250742
[TBL] [Abstract][Full Text] [Related]
31. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction.
Kaneishi K; Kawabata M; Morita T
J Pain Symptom Manage; 2012 Oct; 44(4):604-7. PubMed ID: 22771132
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines.
Tageja N; Groninger H
Postgrad Med J; 2016 Jan; 92(1083):34-40. PubMed ID: 26561590
[TBL] [Abstract][Full Text] [Related]
33. [Medical treatment of chemotherapy-induced nausea and vomiting].
Herrstedt J
Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
[TBL] [Abstract][Full Text] [Related]
34. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting--a systematic review of systematic reviews.
Tafelski S; Häuser W; Schäfer M
Schmerz; 2016 Feb; 30(1):14-24. PubMed ID: 26787227
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of using the Multinational Association of Supportive Care in Cancer Antiemesis Tool for assessment of chemotherapy-induced nausea and vomiting at the Tom Baker Cancer Centre.
Warr JK; Chambers CR; Cusano FL; Cuthbert CA; Mah MS
J Oncol Pharm Pract; 2015 Oct; 21(5):348-57. PubMed ID: 24938292
[TBL] [Abstract][Full Text] [Related]
37. Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting.
Navari RM
Eur J Pharmacol; 2014 Jan; 722():180-6. PubMed ID: 24157985
[TBL] [Abstract][Full Text] [Related]
38. Chinese herbal medicines in the prevention and treatment of chemotherapy-induced nausea and vomiting.
Lv C; Shi C; Li L; Wen X; Xian CJ
Curr Opin Support Palliat Care; 2018 Jun; 12(2):174-180. PubMed ID: 29697417
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
40. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
Tan M; Xu R; Seth R
Curr Med Res Opin; 2004 Jun; 20(6):879-82. PubMed ID: 15200746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
